Clinical relevance of serial quantitative analysis of hematopoietic chimerism after allogeneic stem cell transplantation in children for severe aplastic anemia

Bone Marrow Transplantation

Volumn 33, Issue 2, 2004, Pages 219-223

  Hoelle, W ^a   Beck, J F ^b   Dueckers, G ^a   Kreyenberg, H ^a   Lang, P ^a   Gruhn, B ^d   Fuhrer M ^e   Niethammer, D ^a   Klingebiel, T ^c   Bader, Peter ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d JENA UNIVERSITY HOSPITAL   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Children; Graft rejection; Immunotherapy; Increasing mixed chimerism; SAA

Indexed keywords

BUSULFAN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; THIOTEPA; THYMOCYTE ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; APLASTIC ANEMIA; ARTICLE; BLOOD CELL; CHILD; CHIMERA; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE SEVERITY; GRAFT REJECTION; HUMAN; IMMUNOTHERAPY; LYMPHOCYTE; PATIENT MONITORING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REMISSION; TREATMENT FAILURE;

ADOLESCENT; ANEMIA, APLASTIC; CHILD; CHILD, PRESCHOOL; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHENOTYPE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS;

EID: 10744224569     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704337     Document Type: Article

References (25)

1. Ball SE. The modern management of severe aplastic anaemia. Br J Haematol 2000; 110: 41-53.
2. Mollee P, Woodward N, Durrant S et al. Single institution outcomes of treatment of severe aplastic anaemia. Intern Med J 2001; 31: 337-342.
3. Hows JM, Marsh JC, Yin JL et al. Bone marrow transplantation for severe aplastic anaemia using cyclosporin: long-term follow-up. Bone Marrow Transplant 1989; 4: 11-16.
4. Margolis D, Camitta B, Pietryga D et al. Unrelated donor bone marrow transplantation to treat severe aplastic anaemia in children and young adults. Br J Haematol 1996; 94: 65-72.
5. Bacigalupo A, Brand R, Oneto R et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy - The European Group for Blood and Marrow Transplantation experience. Semin Hematol 2000; 37: 69-80.
6. McCann SR, Bacigalupo A, Gluckman E et al. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group. Bone Marrow Transplant 1994; 13: 233-237.
7. Gomez JR, Garcia MJ, Serrano J et al. Chimerism analysis in long-term survivor patients after bone marrow transplantation for severe aplastic anemia. Haematologica 1997; 82: 588-591.
8. Hill RS, Petersen FB, Storb R et al. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. Blood 1986; 67: 811-816.
9. Lawler M, McCann SR, Gardiner N et al. Mixed chimerism predicts graft rejection following BMT for severe aplastic anaemia. Final report for the EBMT working party on SAA. Bone Marrow Transplant 1995; 15: 64a.
10. Casado LF, Steegmann JL, Pico M et al. Study of chimerism in long-term survivors after bone marrow transplantation for severe acquired aplastic anemia. Bone Marrow Transplant 1996; 18: 405-409.
11. Bader P, Beck J, Frey A et al. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplant 1998; 21: 487-495.
12. Beck JF, Klingebiel T, Kreyenberg H et al. Relapse of childhood ALL, AML and MDS after allogeneic stem cell transplantation can be prevented by donor lymphocyte infusion in a critical stage of increasing mixed chimerism. Klin Padiatr 2002; 214: 201-205.
13. Bader P, Duckers G, Kreyenberg H et al. Monitoring of donor cell chimerism for the detection of relapse and early immunotherapeutic intervention in acute lymphoblastic leukemias. Ann Hematol 2002; 81 (Suppl 2): S25-S27.
14. Fuhrer M, Burdach S, Ebell W et al. Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience German/Austrian Pediatric Aplastic Anemia Working Group. Klin Padiatr 1998; 210: 173-179.
15. Bader P, Holle W, Klingebiel T et al. Quantitative assessment of mixed hematopoietic chimerism by polymerase chain reaction after allogeneic BMT. Anticancer Res 1996; 16: 1759-1763.
16. Kreyenberg H, Holle W, Mohrle S et al. Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Tuebingen experience. Leukemia 2003; 17: 237-240.
17. Lang P, Schumm M, Taylor G et al. Clinical scale isolation of highly purified peripheral CD34 + progenitors for autologous and allogeneic transplantation in children. Bone Marrow Transplant 1999; 24: 583-589.
18. Schumm M, Lang P, Taylor G et al. Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device. J Hematother 1999; 8: 209-218.
19. Klingebiel T, Schlegel PG. GVHD: overview on pathophysiology, incidence, clinical and biological features. Bone Marrow Transplant 1998; 21 (Suppl 2): S45-S49.
20. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
21. Dufour C, Dallorso S, Casarino L et al. Late graft failure 8 years after first bone marrow transplantation for severe acquired aplastic anemia. Bone Marrow Transplant 1999; 23: 743-745.
22. Boiron JM, Cotteret S, Cony-Makhoul P et al. Stable mixed chimerism without relapse after related allogeneic umbilical cord blood transplantation in a child with severe aplastic anemia. Bone Marrow Transplant 1998; 22: 819-821.
23. Bader P, Klingebiel T, Schaudt A et al. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children. Leukemia 1999; 13: 2079-2086.
24. Bader P, Beck J, Schlegel PG et al. Additional immunotherapy on the basis of increasing mixed hematopoietic chimerism after allogeneic BMT in children with acute leukemia: is there an option to prevent relapse? Bone Marrow Transplant 1997; 20: 79-81.
25. Gardiner N, Lawler M, O'Riordan JM et al. Monitoring of lineage-specific chimaerism allows early prediction of response following donor lymphocyte infusions for relapsed chronic myeloid leukaemia. Bone Marrow Transplant 1998; 21: 711-719.